Challenging Cases in Relapsed/Refractory Acute Myeloid Leukemia (AML): Dr. Joshua Zeidner

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of relapsed refractory acute myeloid leukemia (AML) with expert guest Dr. Joshua Zeidner, Chief of Leukemia Research at the University of North Carolina.Join us as we explore two challenging cases:Revumenib (menin inhibitor) demonstrated an overall response rate of ~63% in heavily pre-treated KMT2A rearrangement-positive AML patients based on the AUGMENT-101 study, with QTc prolongation and CYP3A4 drug interactions as key monitoring considerations. FLT3 inhibitors like gilteritinib and quizartinib play an important role in MRD-positive FLT3 ITD/NPM1-mutated AML post-transplant, with the MORPHO trial supporting gilteritinib as maintenance therapy. Menin inhibitors may have a broader role in high-risk AML including NPM1-mutated disease, and re-evaluating mutational profiles at relapse is critical for optimal treatment selection. Careful monitoring of side effect profiles, drug interactions, and MRD status is essential when navigating targeted therapy decisions in relapsed refractory AML.Throughout the episode, we discuss key practical points, including the importance of monitoring for QTc prolongation and the impact of drug interactions with CYP3A4 inhibitors.Tune in for an informative discussion that sheds light on the latest advancements in targeted therapies for AML and the evolving landscape of treatment options.Listen us on:Apple Podcast: ⁠⁠https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966⁠⁠Follow us on social media:X/Twitter: ⁠⁠https://twitter.com/oncbrothers⁠⁠⁠Instagram: ⁠⁠https://www.instagram.com/oncbrothers⁠⁠Website: ⁠⁠https://oncbrothers.com/⁠⁠Don't forget to like, subscribe, and check out our other episodes in the challenging case series, treatment algorithms, and conference highlights!#AcuteMyeloidLeukemia, #MeninInhibitor, #FLT3Inhibitor, #Hematology, #OncologyBrothers